Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Sunrise Group secures FDA clearance for home sleep test
Sunrise Group has secured the US Food and Drug Administration (FDA) clearance for Sunrise Air, its latest rechargeable at-home sleep …
-
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to …
-
SERB signs agreement to acquire Idefirix rights for $133.6m
SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for …
-
Hospital at home: the new model of modern care
Professor Rachid El Fatimy, dean of the Faculty of Medical Sciences and hospital general director at University Mohammed VI Polytechnic …
-
Boston Scientific invests $1.5bn for equity stake in MiRus
Boston Scientific has announced a $1.5bn investment to acquire approximately a 34% equity stake in MiRus, a company developing the …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody …
-
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide …
-
PainTEQ announces US launch of SI joint implant
PainTEQ has announced the commercial launch of TRAQ, an implant developed for posterior sacroiliac (SI) joint fusion, in the US. The …
-
Regeneron’s trial fails to reach statistical significance for primary endpoint
Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab (a LAG-3 inhibitor) and cemiplimab (a PD-1 inhibitor) for …
-
FDA approves Enhertu for two HER2-positive early breast cancer indications
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for two new indications …
-
Ardent Health and Fujifilm team up for Synapse enterprise imaging rollout
Ardent Health has partnered with Fujifilm Healthcare to bring Synapse enterprise imaging solutions to its acute care hospitals across six …
-
Massive Bio and Just Worldwide to expand cancer trial access
Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies. The collaboration will …
-
Kyowa Kirin secures FDA approval for Crysvita dosing update
Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing …
-
Hospitals are treating burnout as a wellness problem. It is an operating model problem
Dr. Michael Suk, CEO of physician advocacy platform MDEnvoy, can discuss the link between physician burnout and turnover, and what this could …
-
Revvity secures FDA clearance for total testosterone immunoassay
Revvity has received clearance from the US Food and Drug Administration (FDA) for its total testosterone automated chemiluminescence immunoassay (ChLIA) …
